Arvinas Inc

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today joined state and local officials, fellow tenants, and community partners, in a groundbreaking ceremony for 101 College Street, a new 525,000-square-foot-building to be constructed as part of New Haven's Downtown Crossing revitalization project. Arvinas will lease three of the 10 floors at 101 College and this space will serve as the Company's headquarters beginning in 2024.

Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven

Annovis Bio

Avadel Pharma

Anavex Life Sciences

Biohaven Pharmaceutical Hld

Denali Therapeutics

Intra-Cellular Therapies

Karuna Therapeutics Inc

Neurocrine Biosciences

Prothena

SAGE Therapeutics

Cassava Sciences Inc

Supernus Pharmaceuticals

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.

Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment

Arvinas went public at $16 on September 26, 2018. The stock zoomed to $92.77 on the early trial successes of its two oncology targets. and currently trades at $67.18.

Connecting The Dots: Are Pfizer And Arvinas At Work On A COVID Cure?

NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Tuesday, May 25 at 10:00 a.m. ET.

Arvinas to Present at the UBS Global Healthcare Virtual Conference

CEVA

eHealth

Hexcel

Workhorse Group

The Dow Jones climbed 220 points, the S&P 500 gained 0.8%, and the Nasdaq recovered another 1%. If you're looking for a way to play this market, the deep learning algorithms at Q.ai have crunched the data to find today's top shorts.

Arvinas Among Top Shorts Today As Dow, S&P 500, And Nasdaq Climb For Another Consecutive Day

– Company to lease approximately 160,000-square-feet to allow continued growth and expansion of operations – – Company to lease approximately 160,000-square-feet to allow continued growth and expansion of operations –

Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -7.69% and 41.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) Reports Q1 Loss, Tops Revenue Estimates

NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update

Bloom Energy

LivePerson

Motorcar Parts of America

Playa Hotels & Resorts

The markets look like they may have a losing week ahead, despite today's gains. If you're looking for opportunities, the deep learning algorithms at Q.ai have crunched the data to give today's top shorts.

Top Stocks To Short Today As Markets Set For Weekly Loss

General Electric

Laureate Education

Sysco

Ventas

The Dow Jones rose over 200 points, the S&P 500 gained 0.7%, and the Nasdaq advanced 1% with excitement over lower-than-expected jobless claims and higher-than-expected retail sales. Make the most of this market with today's best short plays.

Top Stocks To Short Today As Jobless Claims And Retail Sales Crush Estimates

Earlier this year, we talked about why Arvinas stock (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, is vulnerable to downside risk.

Down Over 20% In A Month Can Arvinas Stock Rebound?

NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held virtually from April 10-15, 2021 and May 17-21, 2021. These presentations will describe the discovery of Arvinas' two clinical-stage PROTAC degraders, ARV-110 and ARV-471, including the first disclosures of their structures.

Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

Carvana

NanoString Technologies

Plug Power

Redfin

Investors saw some downwards pressure on the indices to kick off Monday. But Q.ai's deep learning algorithms have crunched the numbers to bring you today's top short plays.

Top Stocks To Short Today Amid More Hedge Fund Problems

PAR Technology

Zovio

Bank shares are leading the way in what looks to be a green day. In the meantime, Q.ai's deep learning algorithms have crunched the numbers to bring you today's top shorts.

Top Stocks To Short Today As Bank Shares Lead The Markets

Allegiant Travel Company

National CineMedia

Today marks the one-year anniversary since the start of the bull market. Make the most of it with today's top short plays from Q.ai's deep learning algorithms.

Best Short Plays Today As Stocks Slip On Anniversary Of Bull Market

NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences. John Houston, Ph.D., President and Chief Executive Officer, will participate in panel discussions at both conferences.

Arvinas to Participate in Upcoming Virtual Investor Conferences

Cardlytics

Sabre

Bond yields are rising again, crushing tech stocks. But the deep learning algorithms at Q.ai have crunched the data to give you a set of Top Shorts for today.

Today's Top Shorts As Tech Stocks Lag With More Rising Bonds

Shares of Arvinas (NASDAQ:ARVN) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share decreased 76.79% year over year to ($0.99), which missed the estimate of ($0.78).

Arvinas: Q4 Earnings Insights

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why

NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on Thursday, February 11 at 4:30 p.m. ET.

Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day

Arvinas is a leader in protein degrader technology. They have shown first outstanding results in phase 1 trials in breast and prostate cancer.

Arvinas: Leading In Cutting Edge Protein Degrader Development

NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced that the underwriters of its previously announced underwritten public offering of common stock, which closed on December 18, 2020, have exercised in full their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. After giving effect to the sale of 857,142 additional shares of common stock in the option closing, the total number of shares of common stock sold by Arvinas in the offering increased to 6,571,428 shares, which resulted in aggregate net proceeds of approximately $431.9 million.   All of the shares were offered by Arvinas.

Arvinas, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares

Foot Locker

GameStop

NetApp

BioAtla, Inc

Coupa Software

Eos Energy Enterprises

Guidewire Software

Jack Henry & Associates

Mustang Bio

Odonate Therapeutics

Upstart Holdings

Vistra Energy

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there has been due to the pandemic resurgence and political issues.

Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More

NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 per share, before underwriting discounts and commissions. In addition, Arvinas has granted the underwriters an option for a period of 30 days to purchase up to an additional 857,142 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares are being offered by Arvinas.

Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock

Arvinas (ARVN) announces promising interim data on its two clinical stage pipeline candidates, ARV-471 and ARV-110, for treating breast cancer and prostate cancer, respectively.

Arvinas (ARVN) Up on Promising Interim Data on Cancer Candidates

News for Arvinas Inc Stock (ARVN)